Skip to main content
S&P 5007,591.70-0.58%DOW52,064.10-0.60%NASDAQ26,081.72-0.65%BTC$76,799.00-1.71%ETH$2,453.65-0.48%GOLD$4,367.20-0.91%OIL$103.26+0.76%
Smart Investors Daily
CR

NASDAQ · CRTX

Cortexyme, Inc.

Healthcare · Biotechnology

$1.95

Up+$0.05 (+2.63%)

Updated Sep 11, 2026, 5:34 AM

SID Score

—

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
70.45M
P/E ratio
-4.2
Dividend yield
0.00%
52-week range
— – —
Volume
272.21K
Avg. volume
453.19K

Price performance

CRTX price history

1M range · 0 trading sessions · Daily adjusted prices

CRTX does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest CRTX news

The latest Smart Investors Daily articles mentioning CRTX.

Stock researchCompany · Overview

CRTX research

Overview

Company profile and research snapshot.

Company profile

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$22.70
Implied upside
—
Analysts
—
CRTX recent ratings
DateFirmRatingTarget
May 11, 2022Credit SuisseUnderperform—
Mar 9, 2022HC Wainwright & Co.Buy—
Jan 28, 2022Canaccord GenuityHold—
Jan 27, 2022JMP SecuritiesMarket Perform—
Oct 27, 2021B of A SecuritiesUnderperform—
Open full forecast

News briefing

No generated briefing is available yet.

defenseworld.net · Dec 2, 2025

Cortexyme (NASDAQ:CRTX) & Eloxx Pharmaceuticals (NASDAQ:ELOX) Head to Head Survey

Institutional and Insider Ownership 2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. Comparatively, 63.2% of Cortexyme shares are held by institutional investors. 20.2% of Eloxx Pharmaceuticals shares are held by insiders. Comparatively, 27.9% of Cortexyme shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By